期刊
ORAL ONCOLOGY
卷 49, 期 8, 页码 733-737出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.oraloncology.2013.03.447
关键词
Tumor suppressor gene; p53; Anti-cancer therapeutics; Head and neck cancer; Oral cancer; Gene therapy; Human papillomavirus
资金
- NCI NIH HHS [R01 CA135096] Funding Source: Medline
Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. (C) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据